Pimecrolimus

Pimecrolimus
Clinical data
Trade names	Elidel
AHFS/Drugs.com	Monograph
Pregnancy; category	AU: B3;
Routes of; administration	topical
Drug class	immunosuppressant
ATC code	D11AH02 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	low systemic absorption
Protein binding	74%–87%
Metabolism	Hepatic CYP3A
Identifiers
	IUPAC name (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-3-{(E)-2-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]-1-methylvinyl}-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosin-1,7,20,21(4H,23H)-tetrone;
CAS Number	137071-32-0 ;
PubChem CID	16051947;
DrugBank	DB00337 ;
ChemSpider	10482089 ;
UNII	7KYV510875;
ChEMBL	ChEMBL1200686 ;
CompTox Dashboard (EPA)	DTXSID2046674 ;
ECHA InfoCard	100.124.895
Chemical and physical data
Formula	C43H68ClNO11
Molar mass	810.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cl[C@@H]1CC[C@H](C[C@H]1OC)\C=C(/C)[C@H]2OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@]3(O)O[C@H]([C@H](C[C@@H](C)CC(\C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]2C)OC)[C@@H](OC)C[C@H]3C;
	InChI InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31+,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1 ; Key:KASDHRXLYQOAKZ-ZPSXYTITSA-N ;
	(what is this?) (verify)

Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema).

It is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel.